Anti-Obesity, Lipid-Lowering, and Anti-Hyperglycemic Effects of CB-02 in High-Fat-Diet-Induced Obese Mice.
| Title: | Anti-Obesity, Lipid-Lowering, and Anti-Hyperglycemic Effects of CB-02 in High-Fat-Diet-Induced Obese Mice. |
|---|---|
| Authors: | Hiep HL; Military Institute of Traditional Medicine, 442 Kim Giang, Dinh Cong, Hanoi 11717, Vietnam.; Bang PV; Military Institute of Traditional Medicine, 442 Kim Giang, Dinh Cong, Hanoi 11717, Vietnam.; Nhan ND; Military Institute of Traditional Medicine, 442 Kim Giang, Dinh Cong, Hanoi 11717, Vietnam.; Ngan NH; Department of Pharmacology, Institute of Pharmacy Education, Vietnam Military Medical University, 160 Phung Hung, Ha Dong, Hanoi 12108, Vietnam.; To DC; Phenikaa University Nano Institute (PHENA), Phenikaa School of Engineering (PSE), Phenikaa University, Nguyen Van Trac, Duong Noi, Hanoi 12116, Vietnam.; Dung NV; Department of Pharmacology, Thai Nguyen University of Medicine and Pharmacy, 284 Luong Ngoc Quyen, Phan Dinh Phung, Thai Nguyen 24124, Vietnam.; Phu LH; Military Institute of Traditional Medicine, 442 Kim Giang, Dinh Cong, Hanoi 11717, Vietnam. |
| Source: | Molecules (Basel, Switzerland) [Molecules] 2025 Sep 10; Vol. 30 (18). Date of Electronic Publication: 2025 Sep 10. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, c1995- |
| MeSH Terms: | Obesity*/drug therapy ; Obesity*/etiology ; Obesity*/metabolism ; Anti-Obesity Agents*/pharmacology ; Anti-Obesity Agents*/chemistry ; Plant Extracts*/pharmacology ; Plant Extracts*/chemistry ; Hypoglycemic Agents*/pharmacology ; Hypoglycemic Agents*/chemistry ; Hypolipidemic Agents*/pharmacology ; Hypolipidemic Agents*/chemistry; Diet, High-Fat/adverse effects ; Blood Glucose/drug effects ; Lipids/blood ; Animals ; Mice ; Mice, Obese ; Male |
| Abstract: | Obesity, along with dyslipidemia and hyperglycemia, is a metabolic disorder growing in prevalence that is linked to chronic diseases such as atherosclerosis, hypertension, and type 2 diabetes. This study evaluated the anti-obesity, lipid-lowering, and anti-hyperglycemic effects of CB-02 capsules containing dry extracts of Phyllanthus emblica L., Dendrobium catenatum Lindl., and Gynostemma pentaphyllum in HFD-induced obese Swiss albino mice. After 12 weeks of HFD induction, mice were treated orally with CB-02 (576 or 1152 mg/kg/day) for 8 weeks. CB-02 significantly reduced BW gain, AC, the Lee obesity index, and the relative weights of visceral fat and major organs. It also improved lipid profiles by decreasing TC, TG, LDL-C, and non-HDL-C, while increasing HDL-C. These effects were comparable to orlistat (60 mg/kg/day). Furthermore, CB-02 lowered fasting glucose and improved insulin sensitivity, as indicated by an increased QUICKI and HOMA-β and reduced HOMA-IR. Histopathological evaluation showed that CB-02 reduced hepatic steatosis and inflammatory cell infiltration and also attenuated β-cell morphological alterations and pancreatic histopathological damage. These results suggest that CB-02 may be a promising therapeutic candidate for managing obesity and its comorbidities, including dyslipidemia, hyperglycemia, and hepatic steatosis, contributing to the prevention of type 2 diabetes and cardiovascular diseases in obese individuals. |
| References: | Mol Biomed. 2025 Apr 25;6(1):25. (PMID: 40278960); Am J Cardiovasc Drugs. 2017 Feb;17(1):27-35. (PMID: 27637494); Toxicol Res (Camb). 2021 Nov 26;10(6):1171-1176. (PMID: 34956620); Rev Cardiovasc Med. 2021 Dec 22;22(4):1279-1293. (PMID: 34957770); Obesity (Silver Spring). 2007 Mar;15(3):600-6. (PMID: 17372309); Food Funct. 2025 Jun 16;16(12):5008-5028. (PMID: 40445062); J Agric Food Chem. 2024 May 8;72(18):10406-10419. (PMID: 38659208); Clin Chem. 1972 Jun;18(6):499-502. (PMID: 4337382); Sci Rep. 2023 Feb 9;13(1):2346. (PMID: 36759688); Front Pharmacol. 2021 Aug 06;12:726528. (PMID: 34421620); Biomed Pharmacother. 2024 Apr;173:116395. (PMID: 38460364); Evid Based Complement Alternat Med. 2012;2012:452313. (PMID: 23125867); Nutrients. 2020 Oct 22;12(11):. (PMID: 33105762); J Agric Food Chem. 2023 Aug 9;71(31):11929-11940. (PMID: 37526282); Cureus. 2024 Aug 21;16(8):e67428. (PMID: 39310549); Clin Med (Lond). 2023 Jul;23(4):357-363. (PMID: 37524411); Metabol Open. 2022 Aug 24;15:100208. (PMID: 36092796); J Ethnopharmacol. 2024 Nov 15;334:118577. (PMID: 39019414); PLoS One. 2025 Jan 6;20(1):e0310458. (PMID: 39761309); Biomedicines. 2025 Feb 18;13(2):. (PMID: 40002915); Curr Obes Rep. 2021 Mar;10(1):14-30. (PMID: 33410104); Phytomedicine. 2023 Jul;115:154834. (PMID: 37094422); Am J Med. 2016 Aug;129(8):879.e1-6. (PMID: 26949003); Endocr Rev. 2007 Oct;28(6):664-84. (PMID: 17785427); Biofactors. 2024 May-Jun;50(3):572-591. (PMID: 38183321); Int J Mol Sci. 2025 Jul 10;26(14):. (PMID: 40724891); Iran J Basic Med Sci. 2023;26(7):738-752. (PMID: 37396948); Obes Res Clin Pract. 2023 Nov-Dec;17(6):449-457. (PMID: 37788944); Obes Rev. 2020 Dec;21(12):e13081. (PMID: 32691524); Curr Protoc Pharmacol. 2012 Sep;Chapter 5:Unit5.61. (PMID: 22948848); Clin Diabetes Endocrinol. 2024 Dec 2;10(1):39. (PMID: 39617908); J Med Food. 2008 Dec;11(4):709-16. (PMID: 19053864); J Clin Med. 2025 Feb 21;14(5):. (PMID: 40094911); Front Pharmacol. 2024 Apr 30;15:1366946. (PMID: 38746011); Diabetol Metab Syndr. 2021 Mar 18;13(1):32. (PMID: 33736684); Front Pharmacol. 2021 Jun 14;12:659626. (PMID: 34194325); BMC Complement Med Ther. 2024 Aug 2;24(1):296. (PMID: 39095777); Arch Pharm Res. 2016 Feb;39(2):221-230. (PMID: 25066072); World J Diabetes. 2023 Mar 15;14(3):130-146. (PMID: 37035220); Nutrients. 2025 May 24;17(11):. (PMID: 40507055); BMC Complement Altern Med. 2019 May 6;19(1):97. (PMID: 31060549); Int J Biol Macromol. 2019 Apr 1;126:209-214. (PMID: 30590141); J Clin Lipidol. 2024 May-Jun;18(3):e320-e350. (PMID: 38664184); Curr Issues Mol Biol. 2024 Sep 20;46(9):10492-10529. (PMID: 39329975); Antioxidants (Basel). 2025 Apr 03;14(4):. (PMID: 40298780); J Sci Food Agric. 2024 Apr;104(6):3437-3447. (PMID: 38111200); Foods. 2024 Mar 28;13(7):. (PMID: 38611346); Nutrients. 2019 Oct 15;11(10):. (PMID: 31618980); Nutr Metab Insights. 2016 Dec 05;9:93-102. (PMID: 27980421); J Ethnopharmacol. 2024 Jan 30;319(Pt 1):117186. (PMID: 37722515); Mol Cell Endocrinol. 2025 May 01;601:112518. (PMID: 40054835); Front Pharmacol. 2023 Jun 20;14:1182937. (PMID: 37408757) |
| Contributed Indexing: | Keywords: CB-02 capsules; Dendrobium catenatum; Gynostemma pentaphyllum; Phyllanthus emblica; dyslipidemia; obesity |
| Substance Nomenclature: | 0 (Anti-Obesity Agents); 0 (Plant Extracts); 0 (Hypoglycemic Agents); 0 (Hypolipidemic Agents); 0 (Blood Glucose); 0 (Lipids) |
| Entry Date(s): | Date Created: 20250927 Date Completed: 20250927 Latest Revision: 20250930 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12472232 |
| DOI: | 10.3390/molecules30183678 |
| PMID: | 41011571 |
| Database: | MEDLINE |
Journal Article